

Paweł, Andrzej Ptaszyński

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/519029/publications.pdf>

Version: 2024-02-01

62
papers

1,773
citations

331670

21
h-index

276875

41
g-index

75
all docs

75
docs citations

75
times ranked

2710
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute STEMI patients undergoing primary PCI. <i>International Journal of Cardiology</i> , 2022, 347, 1-7.	1.7	3
2	Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. <i>Circulation</i> , 2021, 143, 7-17.	1.6	132
3	Percutaneous Occlusion of the Left Atrial Appendage with Thrombus Irrespective to Antithrombotic Therapy. <i>Journal of Clinical Medicine</i> , 2021, 10, 726.	2.4	6
4	Safety of cryoballoon ablation for the treatment of atrial fibrillation: First European results from the cryo AF Global Registry. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 883-894.	1.2	3
5	Impedance fluctuation and steam pop occurrence during radiofrequency current ablation: An experimental in vitro model. <i>Advances in Clinical and Experimental Medicine</i> , 2021, 30, 1051-1056.	1.4	1
6	Diagnosis and management of left atrial appendage thrombus in patients with atrial fibrillation undergoing cardioversion or percutaneous left atrial procedures: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2020, 22, 162-169.	1.7	26
7	Appropriate Shocks and Mortality in Patients With Versus Without Diabetes With Prophylactic Implantable Cardioverter Defibrillators. <i>Diabetes Care</i> , 2020, 43, 196-200.	8.6	11
8	Baseline intrinsic heart rate and response to ivabradine treatment in patients with inappropriate sinus tachycardia. <i>Annals of Noninvasive Electrocardiology</i> , 2020, 25, e12709.	1.1	4
9	Multicentre early experience with totally subcutaneous cardioverter-defibrillators in Poland. <i>Archives of Medical Science</i> , 2020, 16, 764-771.	0.9	3
10	Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. <i>European Heart Journal</i> , 2020, 41, 3437-3447.	2.2	78
11	Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 248.	7.4	134
12	New Polish prototypes of 4- and 8-mm-tip nonirrigated radiofrequency ablation catheters: an in vitro study. <i>Kardiologia Polska</i> , 2020, 78, 1142-1147.	0.6	0
13	Severe atrial fibrosis as a cause of significant intraatrial conduction delay in a patient with scleromyositis. <i>Journal of Electrocardiology</i> , 2019, 56, 77-80.	0.9	1
14	Prediction of mortality benefit based on periodic repolarisation dynamics in patients undergoing prophylactic implantation of a defibrillator: a prospective, controlled, multicentre cohort study. <i>Lancet, The</i> , 2019, 394, 1344-1351.	13.7	49
15	Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2019, 4, 526.	6.1	26
16	Stroke prevention in patients from Latin American countries with nonvalvular atrial fibrillation: Insights from the GARFIELD-AF registry. <i>Clinical Cardiology</i> , 2019, 42, 553-560.	1.8	16
17	Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. <i>American Heart Journal</i> , 2019, 213, 35-46.	2.7	45
18	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD-AF Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e010510.	3.7	44

#	ARTICLE	IF	CITATIONS
19	Statement by a Working Group conceived by the Polish National Consultants in Cardiology and Neurology addressing the use of implantable cardiac monitors in patients after ischaemic embolic stroke of undetermined source. <i>Neurologia i Neurochirurgia Polska</i> , 2019, 53, 181-189.	1.2	1
20	Straight and crozier-shaped catheter techniques for phrenic nerve stimulation during cryoballoon pulmonary vein isolation for the treatment of atrial fibrillation. <i>Kardiologia Polska</i> , 2019, 77, 868-874.	0.6	0
21	Self-terminating ventricular fibrillation recorded by an implantable loop recorder as a cause of syncope – A case report. <i>Journal of Electrocardiology</i> , 2018, 51, 617-619.	0.9	2
22	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. <i>European Heart Journal</i> , 2018, 39, 464-473.	2.2	28
23	Device embolization into the LV following left atrial endage closure with an Amplatzer Amulet. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2018, 52, 171-172.	1.3	2
24	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. <i>Indian Heart Journal</i> , 2018, 70, 828-835.	0.5	16
25	Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. <i>PLoS ONE</i> , 2018, 13, e0191592.	2.5	80
26	Leadless pacemaker and subcutaneous implantable cardioverter-defibrillator therapy: the first use of a novel treatment option in Poland. <i>Kardiologia Polska</i> , 2018, 76, 1026-1026.	0.6	1
27	Combined therapy with cardiac contractility modulation and subcutaneous implantable cardioverter-defibrillator: the first experience in Poland. <i>Kardiologia Polska</i> , 2018, 76, 1740-1740.	0.6	2
28	A local cryotherapy with percutaneous tumour removal as a successful treatment option in patient with tricuspid valve fibroelastoma papillare. <i>European Heart Journal</i> , 2017, 38, ehw516.	2.2	1
29	The clinical value of T-wave alternans derived from Holter monitoring. <i>Europace</i> , 2017, 19, euw292.	1.7	6
30	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. <i>Heart</i> , 2017, 103, 307-314.	2.9	205
31	Impact of gender on event rates at 1-year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. <i>BMJ Open</i> , 2017, 7, e014579.	1.9	30
32	IVABRADINE IN PATIENTS WITH SYMPTOMATIC INAPPROPRIATE SINUS TACHYCARDIA: LONG-TERM OBSERVATIONAL STUDY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 306.	2.8	1
33	Cryoablation for treatment of cardiac arrhythmias: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2017, 19, 303-307.	1.7	7
34	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. <i>BMJ Open</i> , 2017, 7, e017157.	1.9	92
35	Potential benefit of optimizing atrioventricular & interventricular delays in patients with cardiac resynchronization therapy. <i>Indian Journal of Medical Research</i> , 2017, 146, 71.	1.0	4
36	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists. <i>British Journal of Haematology</i> , 2016, 174, 610-623.	2.5	13

#	ARTICLE	IF	CITATIONS
37	Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. <i>European Heart Journal</i> , 2016, 37, 2882-2889.	2.2	222
38	Relationship Between Changes in Pulse Pressure and Frequency Domain Components of Heart Rate Variability During Short-Term Left Ventricular Pacing in Patients with Cardiac Resynchronization Therapy. <i>Medical Science Monitor</i> , 2016, 22, 2043-2049.	1.1	4
39	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. <i>PLoS ONE</i> , 2016, 11, e0164076.	2.5	118
40	Cardiac contractility modulation: a new treatment option for chronic heart failure in Poland. <i>Kardiologia Polska</i> , 2016, 74, 1030-1030.	0.6	0
41	Nieadekwatna tachykardia zatokowa – choroba serca czy zaburzenie zwiĄzane z IÅ™kiem?. <i>Psychiatria I Psychologia Kliniczna</i> , 2016, 16, 126-130.	0.2	0
42	Atypical position of subcutaneous implantable cardioverter-defibrillator as a solution in hypertrophic cardiomyopathy patient with initially negative electrocardiographic screening:. <i>European Heart Journal</i> , 2015, 36, 2542-2542.	2.2	5
43	Renal Denervation – Hypes and Hopes. <i>Cardiovascular Therapeutics</i> , 2015, 33, 141-144.	2.5	2
44	A subcutaneous implantable cardioverter-defibrillator – the first implantation in Poland. <i>Kardiologia Polska</i> , 2015, 73, 62-62.	0.6	4
45	Risk-benefit assessment of ivabradine in the treatment of chronic heart failure. <i>Drug, Healthcare and Patient Safety</i> , 2014, 6, 47.	2.5	5
46	Interventional treatment of atrial fibrillation – contemporary methods and perspectives. <i>Expert Review of Medical Devices</i> , 2014, 11, 595-603.	2.8	0
47	Inflammation and arrhythmias: potential mechanisms and clinical implications. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 1077-1085.	1.5	30
48	Reestratificaci3n en el momento del recambio del desfibrilador autom3tico implantable. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 971-973.	1.2	0
49	Restratification at Time of Implantable Cardioverter Defibrillator Replacement. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 971-973.	0.6	0
50	A New Type of Dual Atrioventricular Nodal Nonreentrant Tachycardia. <i>Annals of Noninvasive Electrocardiology</i> , 2014, 19, 501-503.	1.1	3
51	Inappropriate sinus tachycardia – clinical picture and possible psychogenic basis. <i>Psychiatria I Psychologia Kliniczna</i> , 2014, 14, 245-249.	0.2	0
52	Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive to previous pharmacological therapy. <i>Europace</i> , 2013, 15, 116-121.	1.7	85
53	Noninvasive Assessment of Autonomic Cardiovascular Activity in Patients With Inappropriate Sinus Tachycardia. <i>American Journal of Cardiology</i> , 2013, 112, 811-815.	1.6	14
54	Ivabradine in the Treatment of Inappropriate Sinus Tachycardia in Patients after Successful Radiofrequency Catheter Ablation of Atrioventricular Node Slow Pathway. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2013, 36, 42-49.	1.2	19

#	ARTICLE	IF	CITATIONS
55	Ivabradine in Combination With Metoprolol Succinate in the Treatment of Inappropriate Sinus Tachycardia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 338-344.	2.0	43
56	An electrophysiological approach using 3D electroanatomical mapping system for catheter-based renal denervation: the first Polish experience. <i>Kardiologia Polska</i> , 2013, 71, 990-990.	0.6	1
57	Heart rate turbulence and other autonomic risk markers for arrhythmia risk stratification in dilated cardiomyopathy. <i>Journal of Electrocardiology</i> , 2008, 41, 306-311.	0.9	25
58	Risk stratification after myocardial infarction: a new method of determining the neural component of the baroreflex is potentially more discriminative in distinguishing patients at high and low risk for arrhythmias. <i>Europace</i> , 2008, 10, 227-234.	1.7	3
59	Clinical significance of microvolt T-wave alternans. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2007, 18, 39-44.	0.8	6
60	Quantitative Assessment of Microvolt T-Wave Alternans in Patients with Congestive Heart Failure. <i>Journal of Cardiovascular Electrophysiology</i> , 2005, 16, 620-624.	1.7	72
61	Bedside risk stratification after acute myocardial infarction: Prospective evaluation of the use of heart rate and left ventricular function. <i>Journal of Electrocardiology</i> , 2005, 38, 106-112.	0.9	25
62	Noninvasive arrhythmia risk stratification?update 2003. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2003, 14, 192-198.	0.8	0